| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9169307 | APELLIS PHARMS | Potent compstatin analogs |
Nov, 2027
(4 years from now) | |
| US7989589 | APELLIS PHARMS | Compstatin analogs with improved activity |
Dec, 2027
(4 years from now) | |
| US7888323 | APELLIS PHARMS | Potent compstatin analogs |
Dec, 2027
(4 years from now) | |
| US11661441 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
Jan, 2033
(9 years from now) | |
| US10125171 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
Aug, 2033
(9 years from now) | |
| US10035822 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(10 years from now) | |
| US10875893 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(10 years from now) | |
| US11292815 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9056076 | APELLIS PHARMS | Method of treating age-related macular degeneration comprising administering a compstatin analog |
Oct, 2026
(3 years from now) | |
| US8168584 | APELLIS PHARMS | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
Apr, 2027
(3 years from now) | |
Syfovre is owned by Apellis Pharms.
Syfovre contains Pegcetacoplan.
Syfovre has a total of 10 drug patents out of which 0 drug patents have expired.
Syfovre was authorised for market use on 17 February, 2023.
Syfovre is available in solution;intravitreal dosage forms.
Syfovre can be used as treatment of geographic atrophy secondary to age-related macular degeneration by intravitreal administration of pegcetacoplan and also administering an anti-vegf agent; treatment of geographic atrophy secondary to age-related macular degeneration by intravitreal administration of pegcetacoplan, treatment of geographic atrophy secondary to age-related macular degeneration by administering complement inhibitor pegcetacoplan, treatment of geographic atrophy secondary to age-related macular degeneration by intravitreal administration of pegcetacoplan.
Drug patent challenges can be filed against Syfovre from 2025-05-14.
The generics of Syfovre are possible to be released after 15 November, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Feb 22, 2026 |
| New Chemical Entity Exclusivity (NCE) | May 14, 2026 |
Drugs and Companies using PEGCETACOPLAN ingredient
NCE-1 date: 2025-05-14
Market Authorisation Date: 17 February, 2023
Treatment: Treatment of geographic atrophy secondary to age-related macular degeneration by intravitreal administration of pegcetacoplan; Treatment of geographic atrophy secondary to age-related macular degenera...
Dosage: SOLUTION;INTRAVITREAL
SYFOVRE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic